The role of homologous recombination deficiency testing in ovarian cancer and its clinical implications: do we need it?

The recognition of homologous recombination deficiency (HRD) as a frequent feature of high-grade serous ovarian cancer (HGSOC) has transformed treatment paradigms. Poly(ADP-ribose) polymerase inhibitors (PARPis), developed based on the rationale of synthetic lethality that predicates antitumor effic...

Descripción completa

Detalles Bibliográficos
Autores principales: Ngoi, N.Y.L., Tan, D.S.P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8141874/
https://www.ncbi.nlm.nih.gov/pubmed/34015643
http://dx.doi.org/10.1016/j.esmoop.2021.100144

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8141874/
https://www.ncbi.nlm.nih.gov/pubmed/34015643
http://dx.doi.org/10.1016/j.esmoop.2021.100144

Ejemplares similares